Biotech Values

[swampboots]

As an non-medical observer the editorial was unprecedented, and gave me no assurance the drug had proven to be even mediocre. Further, I would
in my opinion only, advance the notion, that if I was credentialed to see such patients with Alzheimer's, knowledge of an FDA approved "something" drug would finally stop dead in its tracks, the dread I would have explaining to the patient and family that I could not lift a finger to slow the inevitable catastrophic circumstance.. Free of such a burden, I may be less susceptible to forming a bias unfavorable to the discussed drug approval by the FDA, which finally authorizes me to claim to the patient and family I have some sort of remedy to slow the impending rapid brain functioning deterioration.
I would be eager to hear a debate regarding this affair and proposals to remedy the merits of this disputable drug, by other "worthy" leading edge drug trial scholars, published in Nature or similar esteemed publications.